Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor

Márk Barok, Margit Balázs, Péter Nagy, Zsuzsa Rákosy, Andrea Treszl, Eniko Tóth, István Juhász, John W. Park, Jorma Isola, György Vereb, János Szöllosi

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We have recently shown that despite of the fact that the ErbB2-positive JIMT-1 human breast cancer cells intrinsically resistant to trastuzumab in vitro, trastuzumab inhibited the outgrowth of early phase JIMT-1 xenografts in SCID mice via antibody-dependent cellular cytotoxicity (ADCC). Here we show that trastuzumab significantly reduces the number of circulating and disseminated tumor cells (CTCs and DTCs) in this xenograft model system at a time when the primary tumor is already unresponsive to trastuzumab. This observation suggests that ErbB2 positive CTCs and DTCs might be sensitive to trastuzumab-mediated ADCC even if when the primary tumor is already non-responsive. Thus, trastuzumab treatment might also be beneficial in the case of patients with breast cancer that is already trastuzumab resistant.

Original languageEnglish
Pages (from-to)198-208
Number of pages11
JournalCancer Letters
Volume260
Issue number1-2
DOIs
Publication statusPublished - Feb 18 2008

Keywords

  • Breast tumor xenografts
  • Circulating tumor cells
  • Disseminated tumor cells
  • ErbB2/HER2
  • Trastuzumab resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor'. Together they form a unique fingerprint.

  • Cite this